CDK9 and cancer: Furthermore, we successfully demonstrate the feasibility of our idea by creating bispecific DbTACs (bis-DbTACs) sharing one CRBN ligand, which selectively degrades CDK6 (a protein involves in cell proliferation and differentiation) and CDK9 (a protein that participates in transcriptional regulation, DNA repair, and metabolism) in cancer cell lines.